NCT05026736 2025-08-17
Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study
M.D. Anderson Cancer Center
Phase 2 Terminated
Clinical Trials
7 trialsNCT05161572 2025-06-18
NeoRacing
Fudan University
Phase 2 Terminated
NCT05017103 2024-12-11
Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05088967 2024-01-16
Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Terminated
NCT04861948 2022-10-04
IBI188 Combination Therapy in Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Terminated
NCT04653389 2022-01-11
Perioperative Therapy for Hepatocellular Carcinoma
Zhejiang University
Phase 2 Terminated
NCT04427774 2021-07-20
A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Terminated